Sharif Rahmy YOU? Author Swipe

Last 10y

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release Open

Miguel B. Gaspar, Marina Natoli, Laure Castan, Sharif Rahmy, Martin Korade , et al. · 2025

Background AZD5863 is a bispecific T cell engager (TCE) with high affinity to CLDN18.2 and low affinity to cluster of differentiation 3 (CD3), designed to decrease its peripheral cytokine release potential, improve the therapeutic index, a…

1073 AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens Open

Marina Natoli, Sharif Rahmy, Fabien Garçon, Rodrigo Aguilera Olvera, Chelsea Gerada , et al. · 2024

807 The PD1-TIM3 bispecific antibody sabestomig combines with a topoisomerase 1 inhibitor-conjugated ADC for additive anti-tumor activity and tumor immune modulation in a novel humanized NSCLC mouse model Open

Eleanor Clancy‐Thompson, Ivan Inigo, James Moynihan, Paul L. Chariou, Himanshi Desai , et al. · 2024

Supplementary Tables from Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy Open

Sean Murphy, Sharif Rahmy, Dailin Gan, Guoqiang Liu, Yini Zhu , et al. · 2024

Supplementary Table S1, S2, S3, S4, S5

Supplementary Figures from Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy Open

Sean Murphy, Sharif Rahmy, Dailin Gan, Guoqiang Liu, Yini Zhu , et al. · 2024

Supplementary FIgure S1, S2, S3, S4, S5, S6

Data from Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy Open

Sean Murphy, Sharif Rahmy, Dailin Gan, Guoqiang Liu, Yini Zhu , et al. · 2024

Resistance to immune checkpoint blockade (ICB) therapy represents a formidable clinical challenge limiting the efficacy of immunotherapy. In particular, prostate cancer poses a challenge for ICB therapy due to its immunosuppressive feature…

Supplementary Figures from Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy Open

Sean Murphy, Sharif Rahmy, Dailin Gan, Guoqiang Liu, Yini Zhu , et al. · 2024

Supplementary FIgure S1, S2, S3, S4, S5, S6

Data from Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy Open

Sean Murphy, Sharif Rahmy, Dailin Gan, Guoqiang Liu, Yini Zhu , et al. · 2024

Resistance to immune checkpoint blockade (ICB) therapy represents a formidable clinical challenge limiting the efficacy of immunotherapy. In particular, prostate cancer poses a challenge for ICB therapy due to its immunosuppressive feature…

Supplementary Tables from Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy Open

Sean Murphy, Sharif Rahmy, Dailin Gan, Guoqiang Liu, Yini Zhu , et al. · 2024

Supplementary Table S1, S2, S3, S4, S5

Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy Open

Sean Murphy, Sharif Rahmy, Dailin Gan, Guoqiang Liu, Yini Zhu , et al. · 2024

Resistance to immune checkpoint blockade (ICB) therapy represents a formidable clinical challenge limiting the efficacy of immunotherapy. In particular, prostate cancer poses a challenge for ICB therapy due to its immunosuppressive feature…

Acod1 expression in cancer cells promotes immune evasion through the generation of inhibitory peptides Open

James H. Schofield, Joseph Longo, Ryan D. Sheldon, Emma Albano, Abigail E. Ellis , et al. · 2024

Targeting programmed cell death protein 1 (PD-1) is an important component of many immune checkpoint blockade (ICB) therapeutic approaches. However, ICB is not an efficacious strategy in a variety of cancer types, in part due to immunosupp…

P05.01 Sensitizing immunotherapy refractory prostate cancer with optimized ketogenic diet regimen and epigenetic reprogramming Open

Xin Lü, Seán Murphy, Sharif Rahmy, D Gan, J Li , et al. · 2024

Background Resistant to immune checkpoint blockade (ICB) therapy, especially in a few solid tumor types including advanced prostate cancer, represents a formidable clinical challenge. The ketogenic diet can enhance ICB therapy in some canc…

1169 AZD5863: a specific, potent, affinity-optimized claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing Open

Miguel B. Gaspar, Marina Natoli, Laure Castan, Sharif Rahmy, Cathryn Kelton , et al. · 2023

Background Claudin 18.2 (CLDN18.2), a tetraspanin family member essential for the formation of tight junctions,¹ is highly expressed in gastric, pancreatic and esophageal adenocarcinomas, with physiological expression restricted…

Acod1 Expression in Cancer Cells Promotes Immune Evasion through the Generation of Inhibitory Peptides Open

James H. Schofield, Joseph Longo, Ryan D. Sheldon, Emma Albano, Mark A. Hawk , et al. · 2023

Targeting PD-1 is an important component of many immune checkpoint blockade (ICB) therapeutic approaches. However, ICB is not an efficacious strategy in a variety of cancer types, in part due to immunosuppressive metabolites in the tumor m…

Overcome Prostate Cancer Resistance to Immune Checkpoint Therapy with Ketogenic Diet-Induced Epigenetic Reprogramming Open

Seán Murphy, Sharif Rahmy, Dailin Gan, Yini Zhu, M.J. Manyak , et al. · 2023

Advanced prostate cancer (PCa) is overwhelmingly resistant to immune checkpoint blockade (ICB) therapy, representing a formidable clinical challenge. In this study, we developed a syngeneic murine PCa model with acquired ICB resistance. Us…

Acod1 Expression in Cancer Cells Promotes Immune Evasion Through the Generation of Inhibitory Peptides Open

James H. Schofield, Joseph Longo, Ryan D. Sheldon, Emma Albano, Mark A. Hawk , et al. · 2023

Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors Open

Sharif Rahmy, Sanket J. Mishra, Seán Murphy, Brian S. J. Blagg, Xin Lü · 2022

Response resistance to the immune checkpoint blockade (ICB) immunotherapy remains a major clinical challenge that may be overcome through the rational combination of ICB and specific targeted therapeutics. One emerging combination strategy…

Opposing roles of TGFβ and BMP signaling in prostate cancer development Open

Xin Lü, Eun‐Jung Jin, Xi Cheng, Shan Feng, Xiaoying Shang , et al. · 2017

SMAD4 constrains progression of Pten -null prostate cancer and serves as a common downstream node of transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) pathways. Here, we dissected the roles of TGFβ receptor II (TGFBR…

Opposing roles of TGFβ and BMP signaling in prostate cancer development Open

Xin Lü, Eun‐Jung Jin, Xi Cheng, Shan Feng, Xiaoying Shang , et al. · 2017

SMAD4 constrains progression of Pten-null prostate cancer and serves as a common downstream node of transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) pathways. Here, we dissected the roles of TGFβ receptor II (TGFBR2…

Multicellular Tumor Spheroids Combined with Mass Spectrometric Histone Analysis To Evaluate Epigenetic Drugs Open

Peter E. Feist, Simone Sidoli, Xin Liu, Monica M. Schroll, Sharif Rahmy , et al. · 2017

Multicellular tumor spheroids (MCTS) are valuable in vitro tumor models frequently used to evaluate the penetration and efficacy of therapeutics. In this study, we evaluated potential differences in epigenetic markers, i.e., histone post-t…

Fetching topic information...